{"organizations": [], "uuid": "c8ea2ecbf9feaf6539ee44d92454b0b751a438c1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/27/globe-newswire-syneos-health-helps-establish-new-industry-standards-group-to-improve-clinical-trial-collaboration-and-execution.html", "country": "US", "domain_rank": 767, "title": "Syneos Health Helps Establish New Industry Standards Group to Improve Clinical Trial Collaboration and Execution", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.993, "site_type": "news", "published": "2018-03-27T15:05:00.000+03:00", "replies_count": 0, "uuid": "c8ea2ecbf9feaf6539ee44d92454b0b751a438c1"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/27/globe-newswire-syneos-health-helps-establish-new-industry-standards-group-to-improve-clinical-trial-collaboration-and-execution.html", "ord_in_thread": 0, "title": "Syneos Health Helps Establish New Industry Standards Group to Improve Clinical Trial Collaboration and Execution", "locations": [], "entities": {"persons": [{"name": "rachel stahler", "sentiment": "none"}], "locations": [{"name": "raleigh", "sentiment": "none"}, {"name": "n.c.", "sentiment": "none"}], "organizations": [{"name": "globe newswire", "sentiment": "negative"}, {"name": "syneos health helps establish new industry standards group to improve clinical trial collaboration", "sentiment": "negative"}, {"name": "align clinical cro", "sentiment": "none"}, {"name": "syneos health", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "RALEIGH, N.C. , March 27, 2018 (GLOBE NEWSWIRE) -- Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that the company is a founding member of Align Clinical CRO . This new industry technology standards group is dedicated to making it easier for the life sciences industry to run clinical trials with CROs to bring products to market faster and more efficiently.\n“Smart collaboration – identifying better and faster methods to deliver medicines to patients – is at the heart of everything we do at Syneos Health,” says Rachel Stahler, Chief Information Officer. “Within our organization, we’ve purposefully removed the silos between the clinical and commercial disciplines to provide solutions that improve operational delivery and enable our customers to speed therapies to patients. We’re thrilled to bring this spirit of collaboration to Align Clinical CRO, where we’ll work in partnership with our industry peers to transform clinical trial execution.”\nAlign Clinical CRO represents a first-ever global effort where CROs are joining forces to develop open technology standards to transform clinical trial operations. The organization, which launched today, brings together six leading CROs planning to help create open technology standards intended to simplify trial execution and improve the productivity and efficiency of clinical trials for sponsors.\nSyneos Health brings deep industry knowledge to Align Clinical CRO, including in-depth clinical and commercial expertise and integrated, multi-disciplinary perspectives. This knowledge transfer also includes technology competencies such as clinical data systems, as well as commercial insights that can inform accelerated trial design and execution.\n“There’s tremendous potential to enhance clinical trial execution through common technology standards that will benefit the entire industry,” said Henry Levy, President of Align Clinical CRO. “Align Clinical CRO represents an important industry collaboration to improve the trial processes and how the industry works together to accelerate drug development.”\nFor more information on Align Clinical CRO, visit www.alignclinicalcro.org to learn about its mission and stay up-to-date on the standards in development.\nAbout Syneos Health\nSyneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life™ visit syneoshealth.com .\nAbout Align Clinical CRO\nAlign Clinical CRO is an industry standards group founded by Veeva Systems and the world’s largest CROs, including ICON plc, Medpace, Pharmaceutical Product Development LLC (PPD), PRA Health Sciences, Syneos Health, and UBC. The group is dedicated to creating open technology standards that improve trial execution and collaboration with life sciences companies, making it easier for sponsors and CROs to work together during clinical trials. For more information, visit www.alignclinicalcro.org .\nContact: Investor Relations Contact: Press/Media Contact: Ronnie Speight Danielle DeForge Vice President, Investor Relations Senior Director, External Communications +1 919 745 2745 +1 202 210 5992 Investor.Relations@syneoshealth.com danielle.deforge@syneoshealth.com\nSource:Syneos Health", "external_links": ["https://www.globenewswire.com/Tracker?data=aLDo6WVjPPTDqa1VBwcdUMIKb7qY2JWL6fkfnx7YYxwMDiyM2I4LmCDKrHHpZInrqaqZ4WGLQh2aCSo1JTkvoJ2KMKijXTD9UFC63-obAKI=", "https://www.globenewswire.com/Tracker?data=aLDo6WVjPPTDqa1VBwcdUMIKb7qY2JWL6fkfnx7YYxyTovLUHlsjOJ2AbvW_z3b18zUvfGFSemx-Io8lOnRreid-_bD1AYotVNY9UBFw5XE=", "https://www.globenewswire.com/Tracker?data=px5sQqc5jBZ6yy3Hf31Uywb_jORzWCe7JgYMgMEmt4SsaZfmEQtI-hIo-I4r0mR_DewGcIBbX24CRBIyyi1BF2bG3FqMs1634MwP7WfT_sc=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/63aac5a9-9b75-4cca-a492-af2d24cfa331", "https://www.globenewswire.com/Tracker?data=Mu9kZdlwmtfqyHWm1Komt3XiULrdkZqGgSkOJOLDS_rvDuhVEum6CQ4enFbTukMOtMe-vUSSucwhx6whvnndFtWLEdYovCwwHEqpzm0k95k="], "published": "2018-03-27T15:05:00.000+03:00", "crawled": "2018-03-27T18:31:34.001+03:00", "highlightTitle": ""}